Methotrexate therapy of oral corticosteroid‐dependent asthmatics reduces serum immunoglobulins: correlation with clinical response to therapy
Identifieur interne : 001792 ( Istex/Corpus ); précédent : 001791; suivant : 001793Methotrexate therapy of oral corticosteroid‐dependent asthmatics reduces serum immunoglobulins: correlation with clinical response to therapy
Auteurs : C. J. Corrigan ; R. J. Shiner ; B. H. Shakur ; P. W. IndSource :
- Clinical & Experimental Allergy [ 0954-7894 ] ; 2005-05.
English descriptors
- Teeft :
- Allergy, Allergy clin immunol, Asthma, Asthmatic, Asthmatic patients, Baseline, Baseline prednisolone dosages, Blackwell publishing, Clin, Dosage, Experimental allergy, Fev1, Immunoglobulin, Immunol, Individual patients, Leucocyte, Lung function, Methotrexate, Methotrexate therapy, Oral asthmatics, Oral prednisolone, Parametric anova, Percentage changes, Percentage reductions, Prednisolone, Prednisolone dosage, Prednisolone dosages, Responder, Rheumatoid arthritis, Serum concentrations, Severe asthmatics.
Abstract
Background Concomitant methotrexate (MTX) therapy of oral corticosteroid (CS)–dependent asthmatics has been shown to spare CS therapy, but the mechanism is unknown. In a previous report, we showed that MTX increases T cell inhibition by CS. In this report we focus on effects of MTX on immunoglobulin concentrations and their possible clinical relevance. Objective To monitor changes in circulating leucocytes and Ig in a group of these patients during MTX therapy, and to relate these changes to clinical ‘response’ as defined by oral CS reduction. Methods Sixteen severe asthmatics dependent on oral prednisolone 15 (7.5–25) mg/day in addition to high dose inhaled CS were treated with MTX 15 mg intramuscularly, weekly for 28 weeks. Prednisolone dosages were maintained constant for 12 weeks then reduced systematically over the next 16 weeks provided that asthma control did not deteriorate. Patients were classified a priori as ‘responders’ or ‘non‐responders’ to MTX (reduction of initial oral prednisolone requirement by 50% or <50%, respectively). Patients were followed‐up for a further 12 weeks after MTX withdrawal. Serum Ig and differential blood leucocyte counts were measured at baseline, 12, 28 and 40 weeks. Results MTX therapy allowed significant, but individually variable, reductions in oral prednisolone dosages (P<0.00001) without alteration of lung function or symptoms. This was associated with significant reductions in mean serum concentrations of Ig of all classes, which reversed following MTX withdrawal. Reductions in IgE and IgG were significantly greater in the MTX ‘responders’ as compared with ‘non‐responders’, and changes in IgE, IgG and IgM correlated with changes in prednisolone requirements. Differential blood leucocyte counts showed no significant variation. Conclusion MTX therapy reduced oral CS requirements in these severe asthmatics to a degree which correlated with reduced circulating Ig but not lymphopaenia, suggesting a possible cause and effect relationship. These reductions might also contribute to the documented incidence of opportunistic infection in these circumstances.
Url:
DOI: 10.1111/j.1365-2222.2005.02253.x
Links to Exploration step
ISTEX:CEADC4F7ED0E4411128BB58CFFE198D29F8A7087Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Methotrexate therapy of oral corticosteroid‐dependent asthmatics reduces serum immunoglobulins: correlation with clinical response to therapy</title><author><name sortKey="Corrigan, C J" sort="Corrigan, C J" uniqKey="Corrigan C" first="C. J." last="Corrigan">C. J. Corrigan</name><affiliation><mods:affiliation>Guy's, King's & St Thomas'</mods:affiliation></affiliation></author><author><name sortKey="Shiner, R J" sort="Shiner, R J" uniqKey="Shiner R" first="R. J." last="Shiner">R. J. Shiner</name><affiliation><mods:affiliation>Imperial College Schools of Medicine, London, UK</mods:affiliation></affiliation></author><author><name sortKey="Shakur, B H" sort="Shakur, B H" uniqKey="Shakur B" first="B. H." last="Shakur">B. H. Shakur</name><affiliation><mods:affiliation>Imperial College Schools of Medicine, London, UK</mods:affiliation></affiliation></author><author><name sortKey="Ind, P W" sort="Ind, P W" uniqKey="Ind P" first="P. W." last="Ind">P. W. Ind</name><affiliation><mods:affiliation>Imperial College Schools of Medicine, London, UK</mods:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:CEADC4F7ED0E4411128BB58CFFE198D29F8A7087</idno><date when="2005" year="2005">2005</date><idno type="doi">10.1111/j.1365-2222.2005.02253.x</idno><idno type="url">https://api.istex.fr/ark:/67375/WNG-KJ4KSHV8-W/fulltext.pdf</idno><idno type="wicri:Area/Istex/Corpus">001792</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">001792</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main">Methotrexate therapy of oral corticosteroid‐dependent asthmatics reduces serum immunoglobulins: correlation with clinical response to therapy</title><author><name sortKey="Corrigan, C J" sort="Corrigan, C J" uniqKey="Corrigan C" first="C. J." last="Corrigan">C. J. Corrigan</name><affiliation><mods:affiliation>Guy's, King's & St Thomas'</mods:affiliation></affiliation></author><author><name sortKey="Shiner, R J" sort="Shiner, R J" uniqKey="Shiner R" first="R. J." last="Shiner">R. J. Shiner</name><affiliation><mods:affiliation>Imperial College Schools of Medicine, London, UK</mods:affiliation></affiliation></author><author><name sortKey="Shakur, B H" sort="Shakur, B H" uniqKey="Shakur B" first="B. H." last="Shakur">B. H. Shakur</name><affiliation><mods:affiliation>Imperial College Schools of Medicine, London, UK</mods:affiliation></affiliation></author><author><name sortKey="Ind, P W" sort="Ind, P W" uniqKey="Ind P" first="P. W." last="Ind">P. W. Ind</name><affiliation><mods:affiliation>Imperial College Schools of Medicine, London, UK</mods:affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j" type="main">Clinical & Experimental Allergy</title><title level="j" type="alt">CLINICAL EXPERIMENTAL ALLERGY</title><idno type="ISSN">0954-7894</idno><idno type="eISSN">1365-2222</idno><imprint><biblScope unit="vol">35</biblScope><biblScope unit="issue">5</biblScope><biblScope unit="page" from="579">579</biblScope><biblScope unit="page" to="584">584</biblScope><biblScope unit="page-count">6</biblScope><publisher>Blackwell Science Ltd</publisher><pubPlace>Oxford, UK</pubPlace><date type="published" when="2005-05">2005-05</date></imprint><idno type="ISSN">0954-7894</idno></series></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0954-7894</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="Teeft" xml:lang="en"><term>Allergy</term><term>Allergy clin immunol</term><term>Asthma</term><term>Asthmatic</term><term>Asthmatic patients</term><term>Baseline</term><term>Baseline prednisolone dosages</term><term>Blackwell publishing</term><term>Clin</term><term>Dosage</term><term>Experimental allergy</term><term>Fev1</term><term>Immunoglobulin</term><term>Immunol</term><term>Individual patients</term><term>Leucocyte</term><term>Lung function</term><term>Methotrexate</term><term>Methotrexate therapy</term><term>Oral asthmatics</term><term>Oral prednisolone</term><term>Parametric anova</term><term>Percentage changes</term><term>Percentage reductions</term><term>Prednisolone</term><term>Prednisolone dosage</term><term>Prednisolone dosages</term><term>Responder</term><term>Rheumatoid arthritis</term><term>Serum concentrations</term><term>Severe asthmatics</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Background Concomitant methotrexate (MTX) therapy of oral corticosteroid (CS)–dependent asthmatics has been shown to spare CS therapy, but the mechanism is unknown. In a previous report, we showed that MTX increases T cell inhibition by CS. In this report we focus on effects of MTX on immunoglobulin concentrations and their possible clinical relevance. Objective To monitor changes in circulating leucocytes and Ig in a group of these patients during MTX therapy, and to relate these changes to clinical ‘response’ as defined by oral CS reduction. Methods Sixteen severe asthmatics dependent on oral prednisolone 15 (7.5–25) mg/day in addition to high dose inhaled CS were treated with MTX 15 mg intramuscularly, weekly for 28 weeks. Prednisolone dosages were maintained constant for 12 weeks then reduced systematically over the next 16 weeks provided that asthma control did not deteriorate. Patients were classified a priori as ‘responders’ or ‘non‐responders’ to MTX (reduction of initial oral prednisolone requirement by 50% or <50%, respectively). Patients were followed‐up for a further 12 weeks after MTX withdrawal. Serum Ig and differential blood leucocyte counts were measured at baseline, 12, 28 and 40 weeks. Results MTX therapy allowed significant, but individually variable, reductions in oral prednisolone dosages (P<0.00001) without alteration of lung function or symptoms. This was associated with significant reductions in mean serum concentrations of Ig of all classes, which reversed following MTX withdrawal. Reductions in IgE and IgG were significantly greater in the MTX ‘responders’ as compared with ‘non‐responders’, and changes in IgE, IgG and IgM correlated with changes in prednisolone requirements. Differential blood leucocyte counts showed no significant variation. Conclusion MTX therapy reduced oral CS requirements in these severe asthmatics to a degree which correlated with reduced circulating Ig but not lymphopaenia, suggesting a possible cause and effect relationship. These reductions might also contribute to the documented incidence of opportunistic infection in these circumstances.</div></front></TEI><istex><corpusName>wiley</corpusName><keywords><teeft><json:string>prednisolone</json:string><json:string>methotrexate</json:string><json:string>asthmatic</json:string><json:string>responder</json:string><json:string>allergy</json:string><json:string>prednisolone dosages</json:string><json:string>baseline</json:string><json:string>immunoglobulin</json:string><json:string>asthma</json:string><json:string>clin</json:string><json:string>fev1</json:string><json:string>leucocyte</json:string><json:string>immunol</json:string><json:string>serum concentrations</json:string><json:string>oral asthmatics</json:string><json:string>methotrexate therapy</json:string><json:string>blackwell publishing</json:string><json:string>allergy clin immunol</json:string><json:string>experimental allergy</json:string><json:string>individual patients</json:string><json:string>percentage changes</json:string><json:string>percentage reductions</json:string><json:string>dosage</json:string><json:string>baseline prednisolone dosages</json:string><json:string>oral prednisolone</json:string><json:string>severe asthmatics</json:string><json:string>prednisolone dosage</json:string><json:string>asthmatic patients</json:string><json:string>rheumatoid arthritis</json:string><json:string>parametric anova</json:string><json:string>lung function</json:string></teeft></keywords><author><json:item><name>C. J. Corrigan</name><affiliations><json:string>Guy's, King's & St Thomas'</json:string></affiliations></json:item><json:item><name>R. J. Shiner</name><affiliations><json:string>Imperial College Schools of Medicine, London, UK</json:string></affiliations></json:item><json:item><name>B. H. Shakur</name><affiliations><json:string>Imperial College Schools of Medicine, London, UK</json:string></affiliations></json:item><json:item><name>P. W. Ind</name><affiliations><json:string>Imperial College Schools of Medicine, London, UK</json:string></affiliations></json:item></author><subject><json:item><lang><json:string>eng</json:string></lang><value>asthma</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>corticosteroid</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>immunoglobulin</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>lymphocyte</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>methotrexate</value></json:item></subject><articleId><json:string>CEA2253</json:string></articleId><arkIstex>ark:/67375/WNG-KJ4KSHV8-W</arkIstex><language><json:string>eng</json:string></language><originalGenre><json:string>article</json:string></originalGenre><abstract>Background Concomitant methotrexate (MTX) therapy of oral corticosteroid (CS)–dependent asthmatics has been shown to spare CS therapy, but the mechanism is unknown. In a previous report, we showed that MTX increases T cell inhibition by CS. In this report we focus on effects of MTX on immunoglobulin concentrations and their possible clinical relevance. Objective To monitor changes in circulating leucocytes and Ig in a group of these patients during MTX therapy, and to relate these changes to clinical ‘response’ as defined by oral CS reduction. Methods Sixteen severe asthmatics dependent on oral prednisolone 15 (7.5–25) mg/day in addition to high dose inhaled CS were treated with MTX 15 mg intramuscularly, weekly for 28 weeks. Prednisolone dosages were maintained constant for 12 weeks then reduced systematically over the next 16 weeks provided that asthma control did not deteriorate. Patients were classified a priori as ‘responders’ or ‘non‐responders’ to MTX (reduction of initial oral prednisolone requirement by 50% or >50%, respectively). Patients were followed‐up for a further 12 weeks after MTX withdrawal. Serum Ig and differential blood leucocyte counts were measured at baseline, 12, 28 and 40 weeks. Results MTX therapy allowed significant, but individually variable, reductions in oral prednisolone dosages (P>0.00001) without alteration of lung function or symptoms. This was associated with significant reductions in mean serum concentrations of Ig of all classes, which reversed following MTX withdrawal. Reductions in IgE and IgG were significantly greater in the MTX ‘responders’ as compared with ‘non‐responders’, and changes in IgE, IgG and IgM correlated with changes in prednisolone requirements. Differential blood leucocyte counts showed no significant variation. Conclusion MTX therapy reduced oral CS requirements in these severe asthmatics to a degree which correlated with reduced circulating Ig but not lymphopaenia, suggesting a possible cause and effect relationship. These reductions might also contribute to the documented incidence of opportunistic infection in these circumstances.</abstract><qualityIndicators><score>8.559</score><pdfWordCount>3559</pdfWordCount><pdfCharCount>22689</pdfCharCount><pdfVersion>1.3</pdfVersion><pdfPageCount>6</pdfPageCount><pdfPageSize>595.276 x 782.362 pts</pdfPageSize><pdfWordsPerPage>593</pdfWordsPerPage><pdfText>true</pdfText><refBibsNative>true</refBibsNative><abstractWordCount>307</abstractWordCount><abstractCharCount>2128</abstractCharCount><keywordCount>5</keywordCount></qualityIndicators><title>Methotrexate therapy of oral corticosteroid‐dependent asthmatics reduces serum immunoglobulins: correlation with clinical response to therapy</title><pmid><json:string>15898978</json:string></pmid><genre><json:string>article</json:string></genre><host><title>Clinical & Experimental Allergy</title><language><json:string>unknown</json:string></language><doi><json:string>10.1111/(ISSN)1365-2222</json:string></doi><issn><json:string>0954-7894</json:string></issn><eissn><json:string>1365-2222</json:string></eissn><publisherId><json:string>CEA</json:string></publisherId><volume>35</volume><issue>5</issue><pages><first>579</first><last>584</last><total>6</total></pages><genre><json:string>journal</json:string></genre></host><namedEntities><unitex><date><json:string>2005</json:string></date><geogName></geogName><orgName><json:string>Guys Hospital, London SE</json:string><json:string>Blackwell Publishing Ltd</json:string></orgName><orgName_funder></orgName_funder><orgName_provider></orgName_provider><persName><json:string>IgA</json:string><json:string>R. J. Shinerw</json:string><json:string>IgM</json:string><json:string>Guy House</json:string><json:string>IgE</json:string><json:string>In</json:string><json:string>L. Mean</json:string><json:string>Chris Corrigan</json:string><json:string>B. H. Shakurw</json:string><json:string>P. W. Indw</json:string></persName><placeName><json:string>Germany</json:string><json:string>UK</json:string><json:string>Hamburg</json:string><json:string>Ig</json:string></placeName><ref_url></ref_url><ref_bibl><json:string>[14, 15]</json:string><json:string>[4]</json:string><json:string>[12]</json:string><json:string>[11]</json:string><json:string>[21, 22]</json:string><json:string>[10]</json:string><json:string>[3]</json:string><json:string>[20]</json:string><json:string>[8, 9]</json:string><json:string>[5]</json:string><json:string>C. J. Corrigan et al.</json:string><json:string>[13]</json:string><json:string>[19]</json:string></ref_bibl><bibl></bibl></unitex></namedEntities><ark><json:string>ark:/67375/WNG-KJ4KSHV8-W</json:string></ark><categories><wos><json:string>1 - science</json:string><json:string>2 - immunology</json:string><json:string>2 - allergy</json:string></wos><scienceMetrix><json:string>1 - health sciences</json:string><json:string>2 - clinical medicine</json:string><json:string>3 - allergy</json:string></scienceMetrix><scopus><json:string>1 - Life Sciences</json:string><json:string>2 - Immunology and Microbiology</json:string><json:string>3 - Immunology</json:string><json:string>1 - Health Sciences</json:string><json:string>2 - Medicine</json:string><json:string>3 - Immunology and Allergy</json:string></scopus><inist><json:string>1 - sciences appliquees, technologies et medecines</json:string><json:string>2 - sciences biologiques et medicales</json:string><json:string>3 - sciences medicales</json:string></inist></categories><publicationDate>2005</publicationDate><copyrightDate>2005</copyrightDate><doi><json:string>10.1111/j.1365-2222.2005.02253.x</json:string></doi><id>CEADC4F7ED0E4411128BB58CFFE198D29F8A7087</id><score>1</score><fulltext><json:item><extension>pdf</extension><original>true</original><mimetype>application/pdf</mimetype><uri>https://api.istex.fr/ark:/67375/WNG-KJ4KSHV8-W/fulltext.pdf</uri></json:item><json:item><extension>zip</extension><original>false</original><mimetype>application/zip</mimetype><uri>https://api.istex.fr/ark:/67375/WNG-KJ4KSHV8-W/bundle.zip</uri></json:item><istex:fulltextTEI uri="https://api.istex.fr/ark:/67375/WNG-KJ4KSHV8-W/fulltext.tei"><teiHeader><fileDesc><titleStmt><title level="a" type="main">Methotrexate therapy of oral corticosteroid‐dependent asthmatics reduces serum immunoglobulins: correlation with clinical response to therapy</title><title level="a" type="short">Methotrexate therapy of oral corticosteroid‐dependent asthmatics reduces serum Ig</title></titleStmt><publicationStmt><authority>ISTEX</authority><publisher>Blackwell Science Ltd</publisher><pubPlace>Oxford, UK</pubPlace><date type="published" when="2005-05"></date></publicationStmt><notesStmt><note type="content-type" subtype="article" source="article" scheme="https://content-type.data.istex.fr/ark:/67375/XTP-6N5SZHKN-D">article</note><note type="publication-type" subtype="journal" scheme="https://publication-type.data.istex.fr/ark:/67375/JMC-0GLKJH51-B">journal</note></notesStmt><sourceDesc><biblStruct type="article"><analytic><title level="a" type="main">Methotrexate therapy of oral corticosteroid‐dependent asthmatics reduces serum immunoglobulins: correlation with clinical response to therapy</title><title level="a" type="short">Methotrexate therapy of oral corticosteroid‐dependent asthmatics reduces serum Ig</title><author xml:id="author-0000"><persName><forename type="first">C. J.</forename><surname>Corrigan</surname></persName><affiliation><address><addrLine>Guy's</addrLine><addrLine>King's & St Thomas'</addrLine></address></affiliation></author><author xml:id="author-0001"><persName><forename type="first">R. J.</forename><surname>Shiner</surname></persName><affiliation><orgName type="department">Imperial College Schools of Medicine</orgName><address><addrLine>London</addrLine><addrLine>UK</addrLine><country key="GB" xml:lang="en">UNITED KINGDOM</country></address></affiliation></author><author xml:id="author-0002"><persName><forename type="first">B. H.</forename><surname>Shakur</surname></persName><affiliation><orgName type="department">Imperial College Schools of Medicine</orgName><address><addrLine>London</addrLine><addrLine>UK</addrLine><country key="GB" xml:lang="en">UNITED KINGDOM</country></address></affiliation></author><author xml:id="author-0003"><persName><forename type="first">P. W.</forename><surname>Ind</surname></persName><affiliation><orgName type="department">Imperial College Schools of Medicine</orgName><address><addrLine>London</addrLine><addrLine>UK</addrLine><country key="GB" xml:lang="en">UNITED KINGDOM</country></address></affiliation></author><idno type="istex">CEADC4F7ED0E4411128BB58CFFE198D29F8A7087</idno><idno type="ark">ark:/67375/WNG-KJ4KSHV8-W</idno><idno type="DOI">10.1111/j.1365-2222.2005.02253.x</idno><idno type="unit">CEA2253</idno><idno type="supplier">2253</idno><idno type="toTypesetVersion">file:CEA.CEA2253.pdf</idno></analytic><monogr><title level="j" type="main">Clinical & Experimental Allergy</title><title level="j" type="alt">CLINICAL EXPERIMENTAL ALLERGY</title><idno type="pISSN">0954-7894</idno><idno type="eISSN">1365-2222</idno><idno type="book-DOI">10.1111/(ISSN)1365-2222</idno><idno type="book-part-DOI">10.1111/cea.2005.35.issue-5</idno><idno type="product">CEA</idno><idno type="publisherDivision">ST</idno><imprint><biblScope unit="vol">35</biblScope><biblScope unit="issue">5</biblScope><biblScope unit="page" from="579">579</biblScope><biblScope unit="page" to="584">584</biblScope><biblScope unit="page-count">6</biblScope><publisher>Blackwell Science Ltd</publisher><pubPlace>Oxford, UK</pubPlace><date type="published" when="2005-05"></date></imprint></monogr></biblStruct></sourceDesc></fileDesc><encodingDesc><schemaRef type="ODD" url="https://xml-schema.delivery.istex.fr/tei-istex.odd"></schemaRef><appInfo><application ident="pub2tei" version="1.0.10" when="2019-12-20"><label>pub2TEI-ISTEX</label><desc>A set of style sheets for converting XML documents encoded in various scientific publisher formats into a common TEI format.
<ref target="http://www.tei-c.org/">We use TEI</ref></desc></application></appInfo></encodingDesc><profileDesc><abstract xml:lang="en" style="main"><head>Summary</head><p><hi rend="bold">Background
</hi> Concomitant methotrexate (MTX) therapy of oral corticosteroid (CS)–dependent asthmatics has been shown to spare CS therapy, but the mechanism is unknown. In a previous report, we showed that MTX increases T cell inhibition by CS. In this report we focus on effects of MTX on immunoglobulin concentrations and their possible clinical relevance.</p><p><hi rend="bold">Objective
</hi> To monitor changes in circulating leucocytes and Ig in a group of these patients during MTX therapy, and to relate these changes to clinical ‘response’ as defined by oral CS reduction.</p><p><hi rend="bold">Methods
</hi> Sixteen severe asthmatics dependent on oral prednisolone 15 (7.5–25) mg/day in addition to high dose inhaled CS were treated with MTX 15 mg intramuscularly, weekly for 28 weeks. Prednisolone dosages were maintained constant for 12 weeks then reduced systematically over the next 16 weeks provided that asthma control did not deteriorate. Patients were classified <hi rend="italic">a priori</hi> as ‘responders’ or ‘non‐responders’ to MTX (reduction of initial oral prednisolone requirement by <graphic url="ges.gif" rend="geqslant R: gt-or-equal, slanted"></graphic>50% or <50%, respectively). Patients were followed‐up for a further 12 weeks after MTX withdrawal. Serum Ig and differential blood leucocyte counts were measured at baseline, 12, 28 and 40 weeks.</p><p><hi rend="bold">Results
</hi> MTX therapy allowed significant, but individually variable, reductions in oral prednisolone dosages (<hi rend="italic">P</hi><0.00001) without alteration of lung function or symptoms. This was associated with significant reductions in mean serum concentrations of Ig of all classes, which reversed following MTX withdrawal. Reductions in IgE and IgG were significantly greater in the MTX ‘responders’ as compared with ‘non‐responders’, and changes in IgE, IgG and IgM correlated with changes in prednisolone requirements. Differential blood leucocyte counts showed no significant variation.</p><p><hi rend="bold">Conclusion
</hi> MTX therapy reduced oral CS requirements in these severe asthmatics to a degree which correlated with reduced circulating Ig but not lymphopaenia, suggesting a possible cause and effect relationship. These reductions might also contribute to the documented incidence of opportunistic infection in these circumstances.</p></abstract><textClass><keywords xml:lang="en"><term xml:id="k1">asthma</term><term xml:id="k2">corticosteroid</term><term xml:id="k3">immunoglobulin</term><term xml:id="k4">lymphocyte</term><term xml:id="k5">methotrexate</term></keywords><keywords rend="tocHeading1"><term>Original Articles</term></keywords></textClass><langUsage><language ident="en"></language></langUsage></profileDesc><revisionDesc><change when="2019-12-20" who="#istex" xml:id="pub2tei">formatting</change></revisionDesc></teiHeader></istex:fulltextTEI><json:item><extension>txt</extension><original>false</original><mimetype>text/plain</mimetype><uri>https://api.istex.fr/ark:/67375/WNG-KJ4KSHV8-W/fulltext.txt</uri></json:item></fulltext><metadata><istex:metadataXml wicri:clean="Wiley, elements deleted: body"><istex:xmlDeclaration>version="1.0" encoding="UTF-8" standalone="yes"</istex:xmlDeclaration><istex:document><component version="2.0" type="serialArticle" xml:lang="en"><header><publicationMeta level="product"><publisherInfo><publisherName>Blackwell Science Ltd</publisherName><publisherLoc>Oxford, UK</publisherLoc></publisherInfo><doi origin="wiley" registered="yes">10.1111/(ISSN)1365-2222</doi><issn type="print">0954-7894</issn><issn type="electronic">1365-2222</issn><idGroup><id type="product" value="CEA"></id><id type="publisherDivision" value="ST"></id></idGroup><titleGroup><title type="main" sort="CLINICAL EXPERIMENTAL ALLERGY">Clinical & Experimental Allergy</title></titleGroup></publicationMeta><publicationMeta level="part" position="05005"><doi origin="wiley">10.1111/cea.2005.35.issue-5</doi><numberingGroup><numbering type="journalVolume" number="35">35</numbering><numbering type="journalIssue" number="5">5</numbering></numberingGroup><coverDate startDate="2005-05">May 2005</coverDate></publicationMeta><publicationMeta level="unit" type="article" position="7" status="forIssue"><doi origin="wiley">10.1111/j.1365-2222.2005.02253.x</doi><idGroup><id type="unit" value="CEA2253"></id><id type="supplier" value="2253"></id></idGroup><countGroup><count type="pageTotal" number="6"></count></countGroup><titleGroup><title type="tocHeading1">Original Articles</title></titleGroup><eventGroup><event type="firstOnline" date="2005-05-17"></event><event type="publishedOnlineFinalForm" date="2005-05-17"></event><event type="xmlConverted" agent="Converter:BPG_TO_WML3G version:2.3.2 mode:FullText source:FullText result:FullText" date="2010-03-09"></event><event type="xmlConverted" agent="Converter:WILEY_ML3G_TO_WILEY_ML3GV2 version:3.8.8" date="2014-01-09"></event><event type="xmlConverted" agent="Converter:WML3G_To_WML3G version:4.1.7 mode:FullText,remove_FC" date="2014-10-16"></event></eventGroup><numberingGroup><numbering type="pageFirst" number="579">579</numbering><numbering type="pageLast" number="584">584</numbering></numberingGroup><correspondenceTo> Dr Chris Corrigan, Department. of Asthma, Allergy & Respiratory Science, 5th Floor Thomas Guy House, Guys Hospital, London SE1 9RT, UK.
E‐mail: <email normalForm="chris.corrigan@kcl.ac.uk">chris.corrigan@kcl.ac.uk</email></correspondenceTo><linkGroup><link type="toTypesetVersion" href="file:CEA.CEA2253.pdf"></link></linkGroup></publicationMeta><contentMeta><unparsedEditorialHistory>Submitted 13 September 2004; revised 24 January 2005; accepted 25 February 2005</unparsedEditorialHistory><countGroup><count type="figureTotal" number="5"></count><count type="tableTotal" number="1"></count><count type="formulaTotal" number="0"></count><count type="referenceTotal" number="22"></count><count type="wordTotal" number="4214"></count><count type="linksCrossRef" number="43"></count></countGroup><titleGroup><title type="main">Methotrexate therapy of oral corticosteroid‐dependent asthmatics reduces serum immunoglobulins: correlation with clinical response to therapy</title><title type="shortAuthors">C. J. Corrigan <i>et al.</i></title><title type="short">Methotrexate therapy of oral corticosteroid‐dependent asthmatics reduces serum Ig</title></titleGroup><creators><creator creatorRole="author" xml:id="cr1" affiliationRef="#a1"><personName><givenNames>C. J.</givenNames><familyName>Corrigan</familyName></personName></creator><creator creatorRole="author" xml:id="cr2" affiliationRef="#a2"><personName><givenNames>R. J.</givenNames><familyName>Shiner</familyName></personName></creator><creator creatorRole="author" xml:id="cr3" affiliationRef="#a2"><personName><givenNames>B. H.</givenNames><familyName>Shakur</familyName></personName></creator><creator creatorRole="author" xml:id="cr4" affiliationRef="#a2"><personName><givenNames>P. W.</givenNames><familyName>Ind</familyName></personName></creator></creators><affiliationGroup><affiliation xml:id="a1"><unparsedAffiliation>Guy's, King's & St Thomas'</unparsedAffiliation></affiliation><affiliation xml:id="a2" countryCode="GB"><unparsedAffiliation>Imperial College Schools of Medicine, London, UK</unparsedAffiliation></affiliation></affiliationGroup><keywordGroup xml:lang="en"><keyword xml:id="k1">asthma</keyword><keyword xml:id="k2">corticosteroid</keyword><keyword xml:id="k3">immunoglobulin</keyword><keyword xml:id="k4">lymphocyte</keyword><keyword xml:id="k5">methotrexate</keyword></keywordGroup><abstractGroup><abstract type="main" xml:lang="en"><title type="main">Summary</title><p><b>Background
</b> Concomitant methotrexate (MTX) therapy of oral corticosteroid (CS)–dependent asthmatics has been shown to spare CS therapy, but the mechanism is unknown. In a previous report, we showed that MTX increases T cell inhibition by CS. In this report we focus on effects of MTX on immunoglobulin concentrations and their possible clinical relevance.</p><p><b>Objective
</b> To monitor changes in circulating leucocytes and Ig in a group of these patients during MTX therapy, and to relate these changes to clinical ‘response’ as defined by oral CS reduction.</p><p><b>Methods
</b> Sixteen severe asthmatics dependent on oral prednisolone 15 (7.5–25) mg/day in addition to high dose inhaled CS were treated with MTX 15 mg intramuscularly, weekly for 28 weeks. Prednisolone dosages were maintained constant for 12 weeks then reduced systematically over the next 16 weeks provided that asthma control did not deteriorate. Patients were classified <i>a priori</i> as ‘responders’ or ‘non‐responders’ to MTX (reduction of initial oral prednisolone requirement by <inlineGraphic alt="geqslant R: gt-or-equal, slanted" extraInfo="nonStandardEntity" location="ges.gif" href=""></inlineGraphic>50% or <50%, respectively). Patients were followed‐up for a further 12 weeks after MTX withdrawal. Serum Ig and differential blood leucocyte counts were measured at baseline, 12, 28 and 40 weeks.</p><p><b>Results
</b> MTX therapy allowed significant, but individually variable, reductions in oral prednisolone dosages (<i>P</i><0.00001) without alteration of lung function or symptoms. This was associated with significant reductions in mean serum concentrations of Ig of all classes, which reversed following MTX withdrawal. Reductions in IgE and IgG were significantly greater in the MTX ‘responders’ as compared with ‘non‐responders’, and changes in IgE, IgG and IgM correlated with changes in prednisolone requirements. Differential blood leucocyte counts showed no significant variation.</p><p><b>Conclusion
</b> MTX therapy reduced oral CS requirements in these severe asthmatics to a degree which correlated with reduced circulating Ig but not lymphopaenia, suggesting a possible cause and effect relationship. These reductions might also contribute to the documented incidence of opportunistic infection in these circumstances.</p></abstract></abstractGroup></contentMeta></header></component></istex:document></istex:metadataXml><mods version="3.6"><titleInfo lang="en"><title>Methotrexate therapy of oral corticosteroid‐dependent asthmatics reduces serum immunoglobulins: correlation with clinical response to therapy</title></titleInfo><titleInfo type="abbreviated" lang="en"><title>Methotrexate therapy of oral corticosteroid‐dependent asthmatics reduces serum Ig</title></titleInfo><titleInfo type="alternative" contentType="CDATA" lang="en"><title>Methotrexate therapy of oral corticosteroid‐dependent asthmatics reduces serum immunoglobulins: correlation with clinical response to therapy</title></titleInfo><name type="personal"><namePart type="given">C. J.</namePart><namePart type="family">Corrigan</namePart><affiliation>Guy's, King's & St Thomas'</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">R. J.</namePart><namePart type="family">Shiner</namePart><affiliation>Imperial College Schools of Medicine, London, UK</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">B. H.</namePart><namePart type="family">Shakur</namePart><affiliation>Imperial College Schools of Medicine, London, UK</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">P. W.</namePart><namePart type="family">Ind</namePart><affiliation>Imperial College Schools of Medicine, London, UK</affiliation><role><roleTerm type="text">author</roleTerm></role></name><typeOfResource>text</typeOfResource><genre type="article" displayLabel="article" authority="ISTEX" authorityURI="https://content-type.data.istex.fr" valueURI="https://content-type.data.istex.fr/ark:/67375/XTP-6N5SZHKN-D">article</genre><originInfo><publisher>Blackwell Science Ltd</publisher><place><placeTerm type="text">Oxford, UK</placeTerm></place><dateIssued encoding="w3cdtf">2005-05</dateIssued><edition>Submitted 13 September 2004; revised 24 January 2005; accepted 25 February 2005</edition><copyrightDate encoding="w3cdtf">2005</copyrightDate></originInfo><language><languageTerm type="code" authority="rfc3066">en</languageTerm><languageTerm type="code" authority="iso639-2b">eng</languageTerm></language><physicalDescription><extent unit="figures">5</extent><extent unit="tables">1</extent><extent unit="formulas">0</extent><extent unit="references">22</extent><extent unit="linksCrossRef">43</extent><extent unit="words">4214</extent></physicalDescription><abstract lang="en">Background Concomitant methotrexate (MTX) therapy of oral corticosteroid (CS)–dependent asthmatics has been shown to spare CS therapy, but the mechanism is unknown. In a previous report, we showed that MTX increases T cell inhibition by CS. In this report we focus on effects of MTX on immunoglobulin concentrations and their possible clinical relevance. Objective To monitor changes in circulating leucocytes and Ig in a group of these patients during MTX therapy, and to relate these changes to clinical ‘response’ as defined by oral CS reduction. Methods Sixteen severe asthmatics dependent on oral prednisolone 15 (7.5–25) mg/day in addition to high dose inhaled CS were treated with MTX 15 mg intramuscularly, weekly for 28 weeks. Prednisolone dosages were maintained constant for 12 weeks then reduced systematically over the next 16 weeks provided that asthma control did not deteriorate. Patients were classified a priori as ‘responders’ or ‘non‐responders’ to MTX (reduction of initial oral prednisolone requirement by 50% or <50%, respectively). Patients were followed‐up for a further 12 weeks after MTX withdrawal. Serum Ig and differential blood leucocyte counts were measured at baseline, 12, 28 and 40 weeks. Results MTX therapy allowed significant, but individually variable, reductions in oral prednisolone dosages (P<0.00001) without alteration of lung function or symptoms. This was associated with significant reductions in mean serum concentrations of Ig of all classes, which reversed following MTX withdrawal. Reductions in IgE and IgG were significantly greater in the MTX ‘responders’ as compared with ‘non‐responders’, and changes in IgE, IgG and IgM correlated with changes in prednisolone requirements. Differential blood leucocyte counts showed no significant variation. Conclusion MTX therapy reduced oral CS requirements in these severe asthmatics to a degree which correlated with reduced circulating Ig but not lymphopaenia, suggesting a possible cause and effect relationship. These reductions might also contribute to the documented incidence of opportunistic infection in these circumstances.</abstract><subject lang="en"><genre>keywords</genre><topic>asthma</topic><topic>corticosteroid</topic><topic>immunoglobulin</topic><topic>lymphocyte</topic><topic>methotrexate</topic></subject><relatedItem type="host"><titleInfo><title>Clinical & Experimental Allergy</title></titleInfo><genre type="journal" authority="ISTEX" authorityURI="https://publication-type.data.istex.fr" valueURI="https://publication-type.data.istex.fr/ark:/67375/JMC-0GLKJH51-B">journal</genre><identifier type="ISSN">0954-7894</identifier><identifier type="eISSN">1365-2222</identifier><identifier type="DOI">10.1111/(ISSN)1365-2222</identifier><identifier type="PublisherID">CEA</identifier><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>35</number></detail><detail type="issue"><caption>no.</caption><number>5</number></detail><extent unit="pages"><start>579</start><end>584</end><total>6</total></extent></part></relatedItem><relatedItem type="references" displayLabel="cit1"><titleInfo><title>Low‐dose methotrexate spares steroid usage in steroid‐dependent chronic asthmatic patients</title></titleInfo><name type="personal"><namePart type="given">MG.</namePart><namePart type="family">Marin</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Marin MG. Low‐dose methotrexate spares steroid usage in steroid‐dependent chronic asthmatic patients: a meta-analysis. Chest 1997; 112: 29–33.</note><part><date>1997</date><detail type="volume"><caption>vol.</caption><number>112</number></detail><extent unit="pages"><start>29</start><end>33</end></extent></part><relatedItem type="host"><titleInfo><title>a meta-analysis</title></titleInfo><part><date>1997</date><detail type="volume"><caption>vol.</caption><number>112</number></detail><extent unit="pages"><start>29</start><end>33</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit2"><titleInfo><title>Management of steroid‐dependent asthma with methotrexate</title></titleInfo><name type="personal"><namePart type="given">SD</namePart><namePart type="family">Aaron</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">RE</namePart><namePart type="family">Dales</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">B.</namePart><namePart type="family">Pham</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Aaron SD, Dales RE, Pham B. Management of steroid‐dependent asthma with methotrexate: a meta-analysis of randomised clinical trials. Respir Med 1998; 92: 1059–65.</note><part><date>1998</date><detail type="volume"><caption>vol.</caption><number>92</number></detail><extent unit="pages"><start>1059</start><end>65</end></extent></part><relatedItem type="host"><titleInfo><title>a meta-analysis of randomised clinical trials</title></titleInfo><part><date>1998</date><detail type="volume"><caption>vol.</caption><number>92</number></detail><extent unit="pages"><start>1059</start><end>65</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit3"><titleInfo><title>Methotrexate metabolism analysis in blood and liver of rheumatoid arthritis patients</title></titleInfo><name type="personal"><namePart type="given">JM</namePart><namePart type="family">Kremer</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">J</namePart><namePart type="family">Galivan</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">A</namePart><namePart type="family">Streckfuss</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">B.</namePart><namePart type="family">Kamen</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Kremer JM, Galivan J, Streckfuss A, Kamen B. Methotrexate metabolism analysis in blood and liver of rheumatoid arthritis patients: association with hepatic folate deficiency and formation of polyglutamates. Arthritis Rheum 1986; 329: 832–5.</note><part><date>1986</date><detail type="volume"><caption>vol.</caption><number>329</number></detail><extent unit="pages"><start>832</start><end>5</end></extent></part><relatedItem type="host"><titleInfo><title>association with hepatic folate deficiency and formation of polyglutamates</title></titleInfo><part><date>1986</date><detail type="volume"><caption>vol.</caption><number>329</number></detail><extent unit="pages"><start>832</start><end>5</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit4"><titleInfo><title>Methotrexate therapy in asthma increases T cell susceptibility to corticosteroid inhibition</title></titleInfo><name type="personal"><namePart type="given">CJ</namePart><namePart type="family">Corrigan</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">R</namePart><namePart type="family">Shiner</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">BH</namePart><namePart type="family">Shakur</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">PW.</namePart><namePart type="family">Ind</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Corrigan CJ, Shiner R, Shakur BH, Ind PW. Methotrexate therapy in asthma increases T cell susceptibility to corticosteroid inhibition. Clin Exp Allergy 2003; 33: 1090–6.</note><part><date>2003</date><detail type="volume"><caption>vol.</caption><number>33</number></detail><extent unit="pages"><start>1090</start><end>6</end></extent></part><relatedItem type="host"><titleInfo><title>Clin Exp Allergy</title></titleInfo><part><date>2003</date><detail type="volume"><caption>vol.</caption><number>33</number></detail><extent unit="pages"><start>1090</start><end>6</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit5"><titleInfo><title>Treatment of allergic asthma with monoclonal anti‐IgE antibody</title></titleInfo><name type="personal"><namePart type="given">H</namePart><namePart type="family">Milgrom</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">RB</namePart><namePart type="family">Fick</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">JQ</namePart><namePart type="family">Su</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Milgrom H, Fick RB, Su JQ et al. Treatment of allergic asthma with monoclonal anti‐IgE antibody. N Engl J Med 1999; 341: 1966–73.</note><part><date>1999</date><detail type="volume"><caption>vol.</caption><number>341</number></detail><extent unit="pages"><start>1966</start><end>73</end></extent></part><relatedItem type="host"><titleInfo><title>N Engl J Med</title></titleInfo><part><date>1999</date><detail type="volume"><caption>vol.</caption><number>341</number></detail><extent unit="pages"><start>1966</start><end>73</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit6"><titleInfo><title>A placebo‐controlled multicenter study in the treatment of corticosteroid‐dependent chronic severe asthma</title></titleInfo><name type="personal"><namePart type="given">IL</namePart><namePart type="family">Bernstein</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">DI</namePart><namePart type="family">Bernstein</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">JW</namePart><namePart type="family">Dubb</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">I</namePart><namePart type="family">Faiferman</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">B.</namePart><namePart type="family">Wallin</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Bernstein IL, Bernstein DI, Dubb JW, Faiferman I, Wallin B. A placebo‐controlled multicenter study in the treatment of corticosteroid‐dependent chronic severe asthma. J Allergy Clin Immunol 1996; 98: 317–24.</note><part><date>1996</date><detail type="volume"><caption>vol.</caption><number>98</number></detail><extent unit="pages"><start>317</start><end>24</end></extent></part><relatedItem type="host"><titleInfo><title>J Allergy Clin Immunol</title></titleInfo><part><date>1996</date><detail type="volume"><caption>vol.</caption><number>98</number></detail><extent unit="pages"><start>317</start><end>24</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit7"><titleInfo><title>Hydroxychloroquine improves airflow and lowers circulating IgE levels in subjects with moderate symptomatic asthma</title></titleInfo><name type="personal"><namePart type="given">BL</namePart><namePart type="family">Charous</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">EF</namePart><namePart type="family">Halpern</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">GC.</namePart><namePart type="family">Steven</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Charous BL, Halpern EF, Steven GC. Hydroxychloroquine improves airflow and lowers circulating IgE levels in subjects with moderate symptomatic asthma. J Allergy Clin Immunol 1998; 102: 198–203.</note><part><date>1998</date><detail type="volume"><caption>vol.</caption><number>102</number></detail><extent unit="pages"><start>198</start><end>203</end></extent></part><relatedItem type="host"><titleInfo><title>J Allergy Clin Immunol</title></titleInfo><part><date>1998</date><detail type="volume"><caption>vol.</caption><number>102</number></detail><extent unit="pages"><start>198</start><end>203</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit8"><titleInfo><title>Elevated complement C3a in plasma from patients with severe acute asthma</title></titleInfo><name type="personal"><namePart type="given">Y</namePart><namePart type="family">Nakano</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">S</namePart><namePart type="family">Morita</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">A</namePart><namePart type="family">Kawamoto</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Nakano Y, Morita S, Kawamoto A et al. Elevated complement C3a in plasma from patients with severe acute asthma. J Allergy Clin Immunol 2003; 112: 525–30.</note><part><date>2003</date><detail type="volume"><caption>vol.</caption><number>112</number></detail><extent unit="pages"><start>525</start><end>30</end></extent></part><relatedItem type="host"><titleInfo><title>J Allergy Clin Immunol</title></titleInfo><part><date>2003</date><detail type="volume"><caption>vol.</caption><number>112</number></detail><extent unit="pages"><start>525</start><end>30</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit9"><titleInfo><title>Complement in allergy and asthma</title></titleInfo><name type="personal"><namePart type="given">NP</namePart><namePart type="family">Gerard</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">C.</namePart><namePart type="family">Gerard</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Gerard NP, Gerard C. Complement in allergy and asthma. Curr Opin Immunol 2002; 14: 705–8.</note><part><date>2002</date><detail type="volume"><caption>vol.</caption><number>14</number></detail><extent unit="pages"><start>705</start><end>8</end></extent></part><relatedItem type="host"><titleInfo><title>Curr Opin Immunol</title></titleInfo><part><date>2002</date><detail type="volume"><caption>vol.</caption><number>14</number></detail><extent unit="pages"><start>705</start><end>8</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit10"><titleInfo><title>Randomised, double‐blind, placebo‐controlled trial of methotrexate in steroid‐dependent asthma</title></titleInfo><name type="personal"><namePart type="given">RJ</namePart><namePart type="family">Shiner</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">AJ</namePart><namePart type="family">Nunn</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">KF</namePart><namePart type="family">Chung</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">DM.</namePart><namePart type="family">Geddes</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Shiner RJ, Nunn AJ, Chung KF, Geddes DM. Randomised, double‐blind, placebo‐controlled trial of methotrexate in steroid‐dependent asthma. Lancet 1990; 336: 137–40.</note><part><date>1990</date><detail type="volume"><caption>vol.</caption><number>336</number></detail><extent unit="pages"><start>137</start><end>40</end></extent></part><relatedItem type="host"><titleInfo><title>Lancet</title></titleInfo><part><date>1990</date><detail type="volume"><caption>vol.</caption><number>336</number></detail><extent unit="pages"><start>137</start><end>40</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit11"><titleInfo><title>The effects of acute corticosteroid therapy for asthma on serum immunoglobulin levels</title></titleInfo><name type="personal"><namePart type="given">WC</namePart><namePart type="family">Posey</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">HS</namePart><namePart type="family">Nelson</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">B</namePart><namePart type="family">Branch</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Posey WC, Nelson HS, Branch B et al. The effects of acute corticosteroid therapy for asthma on serum immunoglobulin levels. J Allergy Clin Immunol 1978; 62: 340–5.</note><part><date>1978</date><detail type="volume"><caption>vol.</caption><number>62</number></detail><extent unit="pages"><start>340</start><end>5</end></extent></part><relatedItem type="host"><titleInfo><title>J Allergy Clin Immunol</title></titleInfo><part><date>1978</date><detail type="volume"><caption>vol.</caption><number>62</number></detail><extent unit="pages"><start>340</start><end>5</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit12"><titleInfo><title>Immunoglobulin production induced in vitro by glucocorticoid hormones</title></titleInfo><name type="personal"><namePart type="given">J</namePart><namePart type="family">Grayson</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">NJ</namePart><namePart type="family">Pooley</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">IR</namePart><namePart type="family">Koski</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Grayson J, Pooley NJ, Koski IR et al. Immunoglobulin production induced in vitro by glucocorticoid hormones. J Clin Invest 1981; 68: 1539–46.</note><part><date>1981</date><detail type="volume"><caption>vol.</caption><number>68</number></detail><extent unit="pages"><start>1539</start><end>46</end></extent></part><relatedItem type="host"><titleInfo><title>J Clin Invest</title></titleInfo><part><date>1981</date><detail type="volume"><caption>vol.</caption><number>68</number></detail><extent unit="pages"><start>1539</start><end>46</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit13"><titleInfo><title>In vivo effects of glucocorticoids on IgE production</title></titleInfo><name type="personal"><namePart type="given">G</namePart><namePart type="family">Zieg</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">G</namePart><namePart type="family">Lack</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">EJ</namePart><namePart type="family">Harbeck</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Zieg G, Lack G, Harbeck EJ et al. In vivo effects of glucocorticoids on IgE production. J Allergy Clin Immunol 1994; 94: 222–6.</note><part><date>1994</date><detail type="volume"><caption>vol.</caption><number>94</number></detail><extent unit="pages"><start>222</start><end>6</end></extent></part><relatedItem type="host"><titleInfo><title>J Allergy Clin Immunol</title></titleInfo><part><date>1994</date><detail type="volume"><caption>vol.</caption><number>94</number></detail><extent unit="pages"><start>222</start><end>6</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit14"><titleInfo><title>Immunoglobulin and lymphocyte decrease concurrent with adverse reactions induced by methotrexate for RA</title></titleInfo><name type="personal"><namePart type="given">S</namePart><namePart type="family">Inokuma</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">H</namePart><namePart type="family">Kono</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">H</namePart><namePart type="family">Nakayama</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">J.</namePart><namePart type="family">Yamazaki</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Inokuma S, Kono H, Nakayama H, Yamazaki J. Immunoglobulin and lymphocyte decrease concurrent with adverse reactions induced by methotrexate for RA. Ann Rheum Dis 2000; 59: 495–6.</note><part><date>2000</date><detail type="volume"><caption>vol.</caption><number>59</number></detail><extent unit="pages"><start>495</start><end>6</end></extent></part><relatedItem type="host"><titleInfo><title>Ann Rheum Dis</title></titleInfo><part><date>2000</date><detail type="volume"><caption>vol.</caption><number>59</number></detail><extent unit="pages"><start>495</start><end>6</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit15"><titleInfo><title>Immunoglobulin levels in methotrexate treated paediatric rheumatology patients</title></titleInfo><name type="personal"><namePart type="given">OJ</namePart><namePart type="family">Rackham</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">JA</namePart><namePart type="family">Sills</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">JE.</namePart><namePart type="family">Davidson</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Rackham OJ, Sills JA, Davidson JE. Immunoglobulin levels in methotrexate treated paediatric rheumatology patients. Arch Dis Child 2002; 87: 147–8.</note><part><date>2002</date><detail type="volume"><caption>vol.</caption><number>87</number></detail><extent unit="pages"><start>147</start><end>8</end></extent></part><relatedItem type="host"><titleInfo><title>Arch Dis Child</title></titleInfo><part><date>2002</date><detail type="volume"><caption>vol.</caption><number>87</number></detail><extent unit="pages"><start>147</start><end>8</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit16"><titleInfo><title>Methotrexate inhibits the first committed step of purine biosynthesis in mitogen‐stimulated human T‐lymphocytes</title></titleInfo><name type="personal"><namePart type="given">LD</namePart><namePart type="family">Fairbanks</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">K</namePart><namePart type="family">Ruckemann</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Y</namePart><namePart type="family">Qiu</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Fairbanks LD, Ruckemann K, Qiu Y et al. Methotrexate inhibits the first committed step of purine biosynthesis in mitogen‐stimulated human T‐lymphocytes: a metabolic basis for efficacy in rheumatoid arthritis? Biochem J 1999; 342: 143–52.</note><part><date>1999</date><detail type="volume"><caption>vol.</caption><number>342</number></detail><extent unit="pages"><start>143</start><end>52</end></extent></part><relatedItem type="host"><titleInfo><title>a metabolic basis for efficacy in rheumatoid arthritis?</title></titleInfo><part><date>1999</date><detail type="volume"><caption>vol.</caption><number>342</number></detail><extent unit="pages"><start>143</start><end>52</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit17"><titleInfo><title>Molecular action of methotrexate in inflammatory diseases</title></titleInfo><name type="personal"><namePart type="given">ESL</namePart><namePart type="family">Chan</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">BN.</namePart><namePart type="family">Cronstein</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Chan ESL, Cronstein BN. Molecular action of methotrexate in inflammatory diseases. Arthritis Res 2002; 4: 266–73.</note><part><date>2002</date><detail type="volume"><caption>vol.</caption><number>4</number></detail><extent unit="pages"><start>266</start><end>73</end></extent></part><relatedItem type="host"><titleInfo><title>Arthritis Res</title></titleInfo><part><date>2002</date><detail type="volume"><caption>vol.</caption><number>4</number></detail><extent unit="pages"><start>266</start><end>73</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit18"><titleInfo><title>Expression of A2B adenosine receptors in human lymphocytes</title></titleInfo><name type="personal"><namePart type="given">M</namePart><namePart type="family">Mirabel</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">C</namePart><namePart type="family">Herrera</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">OJ</namePart><namePart type="family">Cordero</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Mirabel M, Herrera C, Cordero OJ et al. Expression of A2B adenosine receptors in human lymphocytes: their role in T cell activation. J Cell Sci 1999; 112: 491–502.</note><part><date>1999</date><detail type="volume"><caption>vol.</caption><number>112</number></detail><extent unit="pages"><start>491</start><end>502</end></extent></part><relatedItem type="host"><titleInfo><title>their role in T cell activation</title></titleInfo><part><date>1999</date><detail type="volume"><caption>vol.</caption><number>112</number></detail><extent unit="pages"><start>491</start><end>502</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit19"><titleInfo><title>Effect of low‐dose methotrexate on the disposition of glucocorticoids and theophylline</title></titleInfo><name type="personal"><namePart type="given">AM</namePart><namePart type="family">Glynnbarnhart</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">SC</namePart><namePart type="family">Erzurum</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">JA</namePart><namePart type="family">Leff</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Glynnbarnhart AM, Erzurum SC, Leff JA et al. Effect of low‐dose methotrexate on the disposition of glucocorticoids and theophylline. J Allergy Clin Immunol 1991; 88: 180–6.</note><part><date>1991</date><detail type="volume"><caption>vol.</caption><number>88</number></detail><extent unit="pages"><start>180</start><end>6</end></extent></part><relatedItem type="host"><titleInfo><title>J Allergy Clin Immunol</title></titleInfo><part><date>1991</date><detail type="volume"><caption>vol.</caption><number>88</number></detail><extent unit="pages"><start>180</start><end>6</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit20"><titleInfo><title>IgM‐rheumatoid factor and responses to second‐line drugs in rheumatoid arthritis</title></titleInfo><name type="personal"><namePart type="given">NJ</namePart><namePart type="family">Olsen</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">GP</namePart><namePart type="family">Teal</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">RH.</namePart><namePart type="family">Brooks</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Olsen NJ, Teal GP, Brooks RH. IgM‐rheumatoid factor and responses to second‐line drugs in rheumatoid arthritis. Agents Actions 1991; 34: 169–71.</note><part><date>1991</date><detail type="volume"><caption>vol.</caption><number>34</number></detail><extent unit="pages"><start>169</start><end>71</end></extent></part><relatedItem type="host"><titleInfo><title>Agents Actions</title></titleInfo><part><date>1991</date><detail type="volume"><caption>vol.</caption><number>34</number></detail><extent unit="pages"><start>169</start><end>71</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit21"><titleInfo><title>Fatal varicella‐zoster infection in a severe steroid‐dependent asthmatic patient receiving methotrexate</title></titleInfo><name type="personal"><namePart type="given">AM</namePart><namePart type="family">Morice</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">WK.</namePart><namePart type="family">Lai</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Morice AM, Lai WK. Fatal varicella‐zoster infection in a severe steroid‐dependent asthmatic patient receiving methotrexate. Thorax 1995; 50: 1221–2.</note><part><date>1995</date><detail type="volume"><caption>vol.</caption><number>50</number></detail><extent unit="pages"><start>1221</start><end>2</end></extent></part><relatedItem type="host"><titleInfo><title>Thorax</title></titleInfo><part><date>1995</date><detail type="volume"><caption>vol.</caption><number>50</number></detail><extent unit="pages"><start>1221</start><end>2</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit22"><titleInfo><title>Pneumocystis carinii pneumonia as a complication of methotrexate treatment of asthma</title></titleInfo><name type="personal"><namePart type="given">LM</namePart><namePart type="family">Kuitert</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">AC.</namePart><namePart type="family">Harrison</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Kuitert LM, Harrison AC. Pneumocystis carinii pneumonia as a complication of methotrexate treatment of asthma. Thorax 1991; 46: 936–7.</note><part><date>1991</date><detail type="volume"><caption>vol.</caption><number>46</number></detail><extent unit="pages"><start>936</start><end>7</end></extent></part><relatedItem type="host"><titleInfo><title>Thorax</title></titleInfo><part><date>1991</date><detail type="volume"><caption>vol.</caption><number>46</number></detail><extent unit="pages"><start>936</start><end>7</end></extent></part></relatedItem></relatedItem><identifier type="istex">CEADC4F7ED0E4411128BB58CFFE198D29F8A7087</identifier><identifier type="ark">ark:/67375/WNG-KJ4KSHV8-W</identifier><identifier type="DOI">10.1111/j.1365-2222.2005.02253.x</identifier><identifier type="ArticleID">CEA2253</identifier><accessCondition type="use and reproduction" contentType="copyright">© Wiley. All rights reserved.</accessCondition><recordInfo><recordContentSource authority="ISTEX" authorityURI="https://loaded-corpus.data.istex.fr" valueURI="https://loaded-corpus.data.istex.fr/ark:/67375/XBH-L0C46X92-X">wiley</recordContentSource><recordOrigin>Converted from (version ) to MODS version 3.6.</recordOrigin><recordCreationDate encoding="w3cdtf">2019-11-14</recordCreationDate></recordInfo></mods><json:item><extension>json</extension><original>false</original><mimetype>application/json</mimetype><uri>https://api.istex.fr/ark:/67375/WNG-KJ4KSHV8-W/record.json</uri></json:item></metadata><serie></serie></istex></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/ChloroquineV1/Data/Istex/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001792 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Istex/Corpus/biblio.hfd -nk 001792 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= ChloroquineV1
|flux= Istex
|étape= Corpus
|type= RBID
|clé= ISTEX:CEADC4F7ED0E4411128BB58CFFE198D29F8A7087
|texte= Methotrexate therapy of oral corticosteroid‐dependent asthmatics reduces serum immunoglobulins: correlation with clinical response to therapy
}}
| This area was generated with Dilib version V0.6.33. |  |